B of A Securities Maintains Buy on Bristol-Myers Squibb, Lowers Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Geoff Meacham has maintained a 'Buy' rating on Bristol-Myers Squibb (NYSE:BMY) but lowered the price target from $85 to $80.
July 28, 2023 | 12:59 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
B of A Securities has maintained a 'Buy' rating on Bristol-Myers Squibb but lowered the price target from $85 to $80.
The news is directly related to Bristol-Myers Squibb. While the 'Buy' rating is maintained, the lowering of the price target might indicate a slower growth expectation. However, the impact on the stock price is uncertain as the lowered target is still a 'Buy' signal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100